1/52
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced |
---|
No study sessions yet.
Diagnostic: Identifying nature/origin of lesions (epithelial, muscular, nervous), typing lymphomas/leukemias, defining glomerulonephritis pathogenesis, typing malignant neoplasms; Prognostic: Assessing proliferative activity (Ki-67/Mib-1), identifying genetic mutations (p53, c-erbB-2), evaluating hormone receptors (ER, PgR), and microvessel count;
Therapeutic: Guiding therapies based on hormone receptor status (tamoxifen), C-erbB-2 status (trastuzumab), CD-117 (Glivec), EGFR (cetuximab, erlotinib), VEGF (Bevacizumab), chemoresistance in lung cancer (p53), and immunotherapy (PD-L1).